肿瘤细胞治疗研究
英文原题：Autologous hematopoietic stem cell transplantation conditioning regimens and chimeric antigen receptor T cell therapy in various diseases.
以得出更有效的预处理方案。
自体干细胞移植中的预处理方案已证实可用于多种血液系统疾病及其相关恶性肿瘤；然而，尽管在多种情况下有效，也已记录到不良后果。研究者通过检索PubMed、Google Scholar、EMBASE和Cochrane等数据库中的文献，整理了多种预处理方案。针对不同疾病，采用总生存期（OS）、无进展生存期（PFS）和无白血病生存期（LFS）等多个终点评价并比较方案。研究将变量绘制成图并进行分析，以确定疗效更佳的预处理方案。多发性骨髓瘤中，最有效方案为高剂量美法仑（MEL），剂量200 mg/m²。急性髓系白血病的比较结果显示，白消安（BU）联合MEL在OS方面表现较好，BU联合VP16在LFS方面表现较好。急性淋巴细胞白血病（ALL）中，BU、氟达拉滨和依托泊苷（BuFluVP）能够良好控制疾病，不仅显著改善生存率，而且复发风险较低。不过，就ALL而言，若以改善OS和LFS为目标，研究更倾向采用嵌合抗原受体（CAR）T细胞疗法。对于霍奇金淋巴瘤，按PFS看，米托蒽醌（MITO）/MEL优于卡莫司汀、VP16、阿糖胞苷和MEL组合；按OS看则相反。非霍奇金淋巴瘤患者接受MITO（60 mg/m²）和MEL（180 mg/m²）治疗，结果令人鼓舞。最后，研究评估了淀粉样变性，其中表现较好的方案为MEL 200（200 mg/m²）。本文比较了不同疾病所采用的多种预处理方案。
Conditioning regimens employed in autologous stem cell transplantation have been proven useful in various hematological disorders and underlying malig nancies; however, despite being efficacious in various instances, negative consequences have also been recorded. Multiple conditioning regimens were extracted from various literature searches from databases like PubMed, Google scholar, EMBASE, and Cochrane. Conditioning regimens for each disease were compared by using various end points such as overall survival (OS), progression free survival (PFS), and leukemia free survival (LFS). Variables were presented on graphs and analyzed to conclude a more efficacious conditioning regimen. In multiple myeloma, the most effective regimen was high dose melphalan (MEL) given at a dose of 200/mg/m 2 . The comparative results of acute myeloid leukemia were presented and the regimens that proved to be at an admirable position were busulfan (BU) + MEL regarding OS and BU + VP16 regarding LFS. In case of acute lymphoblastic leukemia (ALL), BU, fludarabine, and etoposide (BuFluVP) conferred good disease control not only with a paramount improvement in survival rate but also low risk of recurrence. However, for ALL, chimeric antigen receptor (CAR) T cell therapy was preferred in the context of better OS and LFS. With respect to Hodgkin's lymphoma, mitoxantrone (MITO)/MEL overtook carmustine, VP16, cytarabine, and MEL in view of PFS and vice versa regarding OS. Non-Hodgkin's lymphoma patients were administered MITO (60 mg/m 2 ) and MEL (180 mg/m 2 ) which showed promising results. Lastly, amyloidosis was considered, and the regimen that proved to be competent was MEL 200 (200 mg/m 2 ). This review article demonstrates a comparison between various conditioning regimens employed in different diseases.
MEMBER ACCOUNT
登录成功会直接打开下一页。
